GlassScriptPhysician profile
Mohammad A Zeibo
NPI 1700935640
$2,836.84
in general payments reported to CMS, 2019-2025
19 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $589 · 2021: $420 · 2022: $427 · 2023: $427 · 2024: $197 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,203.66 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Eisai INC. | $845.59 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $206.06 | 2020-2025 | Epidiolex |
| Sunovion Pharmaceuticals INC. | $130.23 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $81.54 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $66.81 | 2023-2024 | Aptiom |
| Zogenix INC. | $35.30 | 2021 | |
| Acadia Pharmaceuticals INC | $31.98 | 2019-2025 | Daybue |
| Avanir Pharmaceuticals, INC. | $30.30 | 2022 | |
| Merz Pharmaceuticals, LLC | $28.94 | 2025 | Ampyra, Inbrija, Xeomin |
| Otsuka America Pharmaceutical, INC. | $24.33 | 2024 | Rexulti |
| Neurelis, INC. | $23.37 | 2024 | Valtoco |
| Zyla Life Sciences, INC. | $21.86 | 2019 | |
| Sk Life Science, INC. | $20.71 | 2020 | |
| Medtronic Vascular, INC. | $19.42 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.33 | 2022 | |
| Aquestive Therapeutics, INC. | $19.23 | 2020 | |
| Merck Sharp & Dohme LLC | $15.55 | 2021 | |
| Allergan, INC. | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Zeibo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.